Mar 13, 2019 / 12:30PM GMT
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst
All right. Good morning, and welcome to the second day of the Barclays Global Health Care Conference. My name's Geoff Meacham. I'm the Biopharma Analyst here. I've Olivia Brayer from my team on stage with me as well.
And it's our the pleasure to have Eli Lilly up here on stage for a fireside chat. And we have Chief Scientific Officer Dan Skovronsky. Dan, welcome.
Daniel M. Skovronsky - Eli Lilly and Company - Senior VP & Chief Scientific Officer
Yes. Good morning, Geoff. Thanks for having us here.
Questions and Answers:
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research AnalystYes. So the conversations typically on Lilly, I wanted to ask you, it's -- tend to focus on diabetes, and that's probably the most topical. So I guess the first question is, give us a sense for the successes that Trulicity has had commercially. And then maybe what is your kind of
Trustpilot
